Skip to main content
NCBI home page
Cell Death & Disease logoLink to Cell Death & Disease
. 2022 Jul 12;13(7):602. doi: 10.1038/s41419-022-05049-4

Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth

Yuhang Xue 1,#, Kanqiu Jiang 1,#, Li Ou 2,#, Mingjing Shen 1,#, Yi Yang 3, Jingjing Lu 4,✉, Weihua Xu 1,✉
PMCID: PMC9279331  PMID: 35831279

Abstract

Sphingosine kinase 1 (SphK1) and sphingosine kinase (SphK2) are both important therapeutic targets of non-small cell lung cancer (NSCLC). SKI-349 is a novel, highly efficient and small molecular SphK1/2 dual inhibitor. Here in primary human NSCLC cells and immortalized cell lines, SKI-349 potently inhibited cell proliferation, cell cycle progression, migration and viability. The dual inhibitor induced mitochondrial depolarization and apoptosis activation in NSCLC cells, but it was non-cytotoxic to human lung epithelial cells. SKI-349 inhibited SphK activity and induced ceramide accumulation in primary NSCLC cells, without affecting SphK1/2 expression. SKI-349-induced NSCLC cell death was attenuated by sphingosine-1-phosphate and by the SphK activator K6PC-5, but was potentiated by the short-chain ceramide C6. Moreover, SKI-349 induced Akt-mTOR inactivation, JNK activation, and oxidative injury in primary NSCLC cells. In addition, SKI-349 decreased bromodomain-containing protein 4 (BRD4) expression and downregulated BRD4-dependent genes (Myc, cyclin D1 and Klf4) in primary NSCLC cells. At last, SKI-349 (10 mg/kg) administration inhibited NSCLC xenograft growth in nude mice. Akt-mTOR inhibition, JNK activation, oxidative injury and BRD4 downregulation were detected in SKI-349-treated NSCLC xenograft tissues. Taken together, targeting SphK1/2 by SKI-349 potently inhibits NSCLC cell growth in vitro and in vivo.

Subject terms: Non-small-cell lung cancer, Targeted therapies

Introduction

Lung cancer is still a common global malignancy and a leading cause of cancer-related human mortalities [1, 2]. There are two main subtypes of lung cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Among them, NSCLC accounts for over 80–85% of all lung cancer [1, 2]. Metastatic, recurrent and other advanced NSCLC have very limited clinical treatment options and patients are often with extremely poor prognosis [3]. Therefore, uncovering the molecular mechanisms of NSCLC and identifying novel biomarkers could be crucial for early diagnosis and better treatment [4].

Two functional sphingosine kinase (SphK) isoforms, sphingosine kinase 1 (SphK1) and sphingosine kinase (SphK2), are conserved lipid kinases phosphorylating sphingosine to sphingosine-1-phosphate (S1P) [5–8]. Both SphK1 and SphK2 play crucial roles in tumorigenesis and progression of NSCLC and other human cancers, mainly by regulating cell proliferation and apoptosis [5–8]. Liang et al., have reported a SphK1-driven NF-κB/IL-6/STAT3/ sphingosine-1-phosphate receptor 1 (S1PR1) amplification loop, essential for colitis and colitis-associated cancer (CAC) development and progression [9]. Studies have shown that downregulation of LRIG1 (leucine-rich repeat and immunoglobulin-like domain containing) enhanced EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling, promoting malignant behaviors of cancer cells [9, 10].

Song et al., have shown that SphK1 expression is markedly increased in NSCLC, correlating with tumor progression and poor survival of NSCLC patients [11]. Conversely, genetic silencing or pharmacological inactivation of SphK1 robustly enhanced chemotherapeutics-induced apoptosis in NSCLC cells [11]. Zhu et al., found that SphK1 activated Akt signaling and enhanced NSCLC cell invasion and migration [12]. Ma et al., reported that SphK1 overexpression activated signal transducer and activator of transcription 3 (STAT3) signaling and promoted NSCLC cell proliferation and migration [13]. Insulin-like growth factor-1 (IGF-1) increased SphK1 expression and activation, promoting NSCLC epithelial-mesenchymal transition (EMT), cell migration and resistance of paclitaxel [14].

Wang et al., have reported that SphK2 overexpression in NSCLC is correlated with lower overall survival (OS) and disease-free survival [15]. Liu et al., have also demonstrated that SphK2 is overexpressed in NSCLC, and SphK2 knockdown inhibited proliferation and enhanced gefitinib sensitivity in NSCLC cells [16]. SphK2 inhibition, by a small molecule inhibitor ABC294640, enhanced TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced antitumor activity in NSCLC cells [17]. Therefore, targeting SphK1 and SphK2 could result in promising anti-NSCLC cell activity.

SKI-178, or 3-(4-methoxyphenyl)-1H-pyrazole-5-carboxylic acid, 2-[1-(3,4-dimethoxyphenyl)ethylidene]hydrazide, is a potent SphK1 and SphK2 dual inhibitor [18, 19]. It has displayed significant cytotoxic and pro-apoptotic activity in acute myeloid leukemia (AML) cells [18, 19]. Using the structure guided approach, Hengsta and colleagues modified the linker region between the substituted phenyl rings of SKI-178 and developed a SKI-178 congener, namely SKI-349 [20]. As compared to SKI-178, SKI-349 showed log-fold enhancements in both SphK inhibition and cytotoxic potency against AML cells [20]. Considering that SphK1 and SphK2 are both important therapeutic targets of NSCLC and SKI-349 is a potent SphK1/2 dual inhibitor, the current study explored the potential anti-cancer activity and the possible underlying mechanisms of SKI-349 in NSCLC cells.

Materials and methods

Chemicals and reagents

The fluorescence dyes utilized in the study were described previously [21, 22]. Annexin V-propidium iodide (PI) FACS (fluorescence-activated cell sorting) kit was purchased from Thermo-Fisher Invitrogen Co. (Shanghai, China). Antibodies for SphK2 (#32346), BRD4 (bromodomain-containing protein 4, #13440), p-JNK1/2 (Thr183/Tyr185, #4671) and JNK1 antibody (#3708) were purchased from Cell Signaling Technologies (Beverly, MA). Antibodies for tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, #3219), cytochrome c (Cyto-C, #4280), cathepsin B (#31718), cathepsin D (#69854), Bax (#89477) were from Signaling Tech. The anti-tBid was provided by Abcam (ab10640). Other antibodies in this study were reported previously [21, 22]. K6PC-5 was provided by Dr. Liu at Jiangsu University [23]. Sphingosine-1-phosphate (S1P) was described previously [21]. SKI-349, (4-Amino-2-((4-methoxyphenyl)amino)thiazol-5-yl)(3,4-dimethoxyphenyl)methanone, was synthesized by Shanghai Ruilu Biotech. C6 ceramide was provided by Dr. Chen [24, 25]. The SphK1 inhibitor PF-543, BML-258 and FTY720, the SphK2 specific inhibitor ABC294640 were purchased from Selleck (Shanghai, China). N-acetylcysteine (NAC) and the JNK inhibitor SP600125 were purchased from Sigma-Aldrich (St. Louis, MO). The cell culture reagents were all provide by Hyclone Co. (Logan, UT). For in vitro experiments, all inhibitors or reagents were first dissolved in DMSO (except for NAC) to make stock solutions, which were then added to cell medium with the final DMSO concentration <0.1% (vehicle). NAC was dissolved in PBS. The concentrations of the SphK1 inhibitor PF-543 BML-258 and FTY720 [26, 27] or the SphK2 specific inhibitor ABC294640 [17, 24, 28, 29], utilized at 10–25 μM, were chosen based on the literatures. NAC was dissolved in PBS. In the pre-experiments, we tested SKI-349 concentrations starting from 0.001–0.1 μM in different human NSCLC cells. None of these lower concentrations showed any significant anti-proliferative, cytotoxic and pro-apoptotic activities against the NSCLC cells.

Cell culture

The immortalized NSCLC cell lines, A549 and NCI-H1944, the patient-derived primary human NSCLC cells, pNSCLC-1, pNSCLC-2 and pNSCLC-3 (derived from three different written-informed consent patients), as well as the BEAS-2B lung (bronchial) epithelial cells and the primary human lung epithelial cells were described in our previous studies [21, 22]. A549, NCI-H1944 and BEAS-2B cells were maintained in DMEM medium plus 8–10% FBS. The primary NSCLC cells and primary human lung epithelial cells were maintained in high glucose DMEM medium with 12% FBS plus different growth factors [21]. The gene-alteration profiles of A549 cells were reported previously [30]. NCI-H1944 cell line has mutations in KRAS and ATR. All three primary NSCLC cells PTEN depletion, PI3KCA and KRAS mutations. The protocols were in according to the principles of Declaration of Helsinki and were approved by the Ethics Committee of Soochow University (SDM2021-1103). Mycoplasma and microbial contamination examination were checked every month, with cell doubling time, colony forming efficiency, and morphology verified routinely.

Cellular function studies

Normal distribution was assumed for all endpoints. For in vitro experiments, the estimated sample sizes were exceeded to ensure enough power and using standard deviations (SD). In addition, in vitro experiments were repeated in different NSCLC cells to enhance the power and the confidence of the result outcomes. Each in vitro cellular experiments were repeated five times. NSCLC cells or the epithelial cells were distributed into 96-well/12-well/6-well plates or tissue culturing slides at 70–80% confluence and treated with SKI-349 (at the applied concentrations) or the vehicle control. Cells were then maintained in the conditional medium for indicated time periods and were subject to different cellular functional assays. Cell counting kit-8 (CCK-8) viability assay, colony formation, propidium iodide (PI)-FACS, cell proliferation detection by measuring nuclear 5-ethynyl-2'-deoxyuridine (EdU) staining, BrdU incorporation ELISA assay, the in vitro cell migration/invasion by the “Transwell”/“Matrigel Transwell” assays, cell apoptosis detection by measuring the nuclear terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) staining and Annexin V-PI FACS, the caspase-3 and caspase-7 activity assays, trypan blue-staining assay of cell death, mitochondrial depolarization detection by measuring JC-1 green monomer intensity, reactive oxygen species (ROS) detection by the CellROX dye assay, lipid peroxidation detection by the thiobarbituric acid reactive substances (TBAR) activity assay were described in detail in our previous studies [21, 22, 31, 32]. Assays of the SphK activity and ceramide contents were described previously as well [21]. For “Transwell” studies, cells with SKI-349 treatment were allowed to migrate for only 24 h, and no significant cytotoxicity was yet detected.

Gene and protein expression detection

The detailed protocols of Western blotting, quantitative real time-PCR (qRT-PCR), and data quantification were described in our previously studies [21, 22]. The verified mRNA primers were provided by Genechem (Shanghai, China). The uncroppred Western blotting images were presented in Fig. S1.

Constitutively-active mutant Akt1

As reported [21], the recombinant constitutively-active Akt1 (caAkt1, S473D) adenoviral construct was transduced to pNSCLC-1 cells, and stable cells established by FACS sorting and selection. caAkt1 expression in the stable cells was verified by Western blotting.

BRD4 overexpression

A BRD4 expression GV248 lentiviral construct was provided by Dr. Zheng [33] and was transduced to primary human NSCLC cells. Puromycin was then added to select stable cells for another 24 h. Expression of BRD4 was verified by Western blotting.

SphK1/2 dual silencing

The SphK1 shRNA lentiviral particles and SphK2 shRNA lentiviral particles, both from Santa Cruz Biotech (Santa Cruz, CA), were together added to primary human NSCLC cells for 36 h. Puromycin was then added to select stable cells for another 24 h. Expression of SphK1/2 in the stable cells was tested by Western blotting.

Tumor xenograft studies

The nude mice (18.5–19.0 g, 5–6 week old, half male hale female) were maintained under the Animal Facility of Soochow University. pNSCLC-1 cells (6 × 106 cells per mouse) were subcutaneously (s.c.) injected to the flanks of the nude mice. The patient-derived xenograft (PDX) NSCLC model was established by subcutaneous injection of pNSCLC-1 primary cells (6 × 106 for each mouse) to the nude mice. pNSCLC-1 xenografts were formed 20 days following initial cell injection, with tumor volume close to 100 mm3 (“Day-0”). pNSCLC-1 xenograft-bearing nude mice were then intraperitoneally injected with SKI-349 (at 10 mg/kg body weight, every other day, for seven times/14 days [18]) or the vehicle control (“Veh”, [18]). The tumor volumes were calculated using the described formula [21] and recorded weekly from “Day-0” to “Day-42”. For animal xenograft studies, power and sample sizes were estimated using empirical data from extensive experience in our lab for the expected SD and were supported by the current sample size calculators. All animal procedures were approved by IACUC (institutional animal care and use committee) and Ethic Committee of Soochow University (SDM2021-1103).

Statistical analysis

Data were always with normal distribution and were presented as mean ± SD. The one-way analysis of variance (ANOVA) plus Tukey’s multiple comparison test (GraphPad Prism 5.01) were utilized for the comparison of multiple groups. For comparison between two groups, the Student t test (Excel 2007) was utilized. IC-50 was calculated by nonlinear regression analysis using GraphPad Prism 5.01. P-values < 0.05 were statistically significant.

Results

SKI-349 potently inhibits NSCLC cell progression in vitro

SKI-349 efficiently decreased pNSCLC-1 cell viability in a concentration-dependent manner (Fig. 1A). At 1–10 μM, SKI-349-induced viability (CCK-8 OD) reduction was significant (Fig. 1A). The SphK1/2 dual inhibitor displayed a time-dependent response as well in decreasing pNSCLC-1 cell viability, as it required at least 48 h to produce significant viability reduction (Fig. 1A), which was lasted for at least 96 h (Fig. 1A). Figure 1B demonstrated that SKI-349 decreased the number of viable pNSCLC-1 cell colonies and it was significant at 1–10 μM (Fig. 1B).

Fig. 1. SKI-349 potently inhibits NSCLC cell progression in vitro.

Fig. 1

Open in a new tab

The patient-derived primary NSCLC cells, pNSCLC-1, were treated with SKI-349 at the applied concentration or the vehicle control (“Veh”, 0.1% DMSO), and cells were further cultivated for designated time; Cell viability (by measuring CCK-8 OD, A), colony number (B) and cell proliferation (by testing BrdU incorporation and EdU-positive nuclei percentage, C–E) as well as cell cycle distributions (F), in vitro cell migration and invasion (G, H) were examined by the designated assays. The patient-derived primary NSCLC cells (pNSCLC-2 and pNSCLC-3), the immortalized cell lines (A549 and NCI-H1944), the BEAS-2B lung epithelial cells or the primary human lung epithelial cells (pEpi) were treated with SKI-349 (5 μM, except for I) or the vehicle control (“Veh”, 0.1% DMSO), and cells were further cultivated for designated time; Cell viability (I and L), proliferation (by measuring the EdU-positively-stained nuclei percentage, J and M) and in vitro cell migration (“Transwell” assays, K and N) were tested. Data were presented as mean ± SD (n = 5). *P < 0.05 versus “Veh” treatment. “n.s.” stands for non-statistical difference (P > 0.05) (L–N). Experiments in this figure were repeated five times, and similar results were obtained. Scale bar = 100 μm.

SKI-349, at 1–10 μM, potently inhibited BrdU incorporation in pNSCLC-1 cells, suggesting its anti-proliferative activity (Fig. 1C). Moreover, the percentage of EdU-positively stained nuclei was significantly decreased in SKI-349 (1–10 μM)-treated pNSCLC-1 cells (Fig. 1D, E), further supporting the anti-proliferative activity by the dual inhibitor. The results of these titration experiments (Fig. 1A–E) showed that 5 μM of SKI-349 induced robust anti-cancer activity in NSCLC cells, and this concentration was close to IC-50 (the concentration resulting in 50% CCK-8 OD reduction), this concentration was selected for the following studies.

Next we tested whether the dual inhibitor could affect cell cycle progression. Following SKI-349 (5 μM) treatment, the G1-phase pNSCLC-1 cell percentage was significantly increased, whereas the S-phase cell percentage was decreased (Fig. 1F). These results implied that the dual inhibitor induced G1-S arrest in primary NSCLC cells. Furthermore, SKI-349 (5 μM, for 24 h) potently inhibited pNSCLC-1 cell in vitro migration and invasion (Fig. 1G–H).

Experiments were carried out to further study the potential activity of SKI-349 in other NSCLC cells. The primary NSCLC cells deriving from two other primary patients (pNSCLC-2 and pNSCLC-3, see our previous study [21]) and the immortalized NSCLC cell lines (A549 and NCI-H1944) were subject to SKI-349 treatment. The CCK-8 viability assay results showed that SKI-349, in a dose-dependent manner, deceased viability in the tested primary and immortalized human NSCLC cells (Fig. 1I). The IC-50 was again close to 5 μM in the tested NSCLC cells (Fig. 1I). Moreover, SKI-349 (5 μM) inhibited cell proliferation (EdU-positive nuclei percentage reduction, Fig. 1J) and migration (“Transwell” assays, Fig. 1K). These results clearly supported the anti-NSCLC cell activity by the SphK1/2 dual inhibitor. We also tested the potential effect of SKI-349 on the non-cancerous normal epithelial cells. In BEAS-2B lung epithelial cells and primary human lung epithelial cells (“pEpi”) [21], SKI-349 (5 μM) treatment failed to exert significant inhibition on cell viability (CCK-8 OD, Fig. 1L), proliferation (EdU-positive nuclei percentage, Fig. 1M) and migration (Fig. 1N). These results implied a cancer cell-specific effect by the dual inhibitor.

SKI-349 provokes apoptosis in NSCLC cells

SphK inhibition can induce significant apoptosis activation in NSCLC cells [11, 13, 16, 17]. Next, we tested the potential effect of SKI-349 on cell apoptosis. Treatment with SKI-349 (5 μM, 48 h) robustly increased the caspae-3 activity and the caspase-7 activity in pNSCLC-1 primary cells (Fig. 2 A). Figure 2B confirmed that cleavages of caspae-3, caspase-9 and PARP [poly(ADP-ribose) polymerase] were increased in SKI-349-treated pNSCLC-1 cells. SKI-349 failed to significantly increase TRAIL expression and caspase-8 cleavage in pNSCLC-1 cells (Fig. 2B). Insertion of homo/hetero-oligomerized Bax and Bak into the mitochondrial outer membrane led to pore formation, membrane permeabilization, and depolarization of the mitochondria, which will cause Cyto-C release and mitochondrial apoptosis cascade activation [34, 35]. We found that the cytosol cytochrome c release and Bax expression were significantly increased in pNSCLC-1 cells after SKI-349 treatment (Fig. 2C). The dual inhibitor also induced significant mitochondrial depolarization, which was evidenced by the accumulation of JC-1 green monomer (Fig. 2D).

Fig. 2. SKI-349 provokes apoptosis in NSCLC cells.

Fig. 2

Open in a new tab

The patient-derived primary human NSCLC cells, pNSCLC-1, were treated with SKI-349 (5 μM) or the vehicle control (“Veh”, 0.1% DMSO), and cells were further cultivated for designated time; The relative caspase-3 and caspase-7 activities (A), expression of the apoptosis-associated proteins (B, C) and depolarization of mitochondria (by measuring JC-1 green monomer intensity, (D)) were tested. Cell apoptosis was tested by measuring TUNEL-positively stained nuclei percentage (E) and Annexin-V positively gated cell percentage (F). Cell death was tested by measuring the ratio of Trypan blue positively-stained cells (G). pNSCLC-1 cells were pretreated with z-DEVD-fmk (45 μM, 30 min pretreatment) or vehicle control (0.1% DMSO), followed by SKI-349 (5 μM) stimulation and cultivated for additional 72 h, cell viability (by measuring CCK-8 OD) and death (by measuring Trypan blue positively-stained cells) were tested (H). The patient-derived primary NSCLC cells (pNSCLC-2 and pNSCLC-3), the immortalized cell lines (A549 and NCI-H1944), the BEAS-2B lung epithelial cells or the primary human lung epithelial cells (pEpi) were treated with SKI-349 (5 μM, expect for (I)) or the vehicle control (“Veh”, 0.1% DMSO), and cells were cultivated for designated time; cell death (I and N), relative caspase-3 activity (J), depolarization of mitochondria (K), cell apoptosis (L, M) were tested using the described methods. Data were presented as mean ± SD (n = 5). *P < 0.05 versus “Veh” treatment. #P < 0.05 (H). “n.s.” stands for non-statistical difference (P > 0.05, B, M, N). Experiments in this figure were repeated five times, and similar results were obtained. Scale bar = 100 μm.

Nuclear TUNEL staining assay results supported that SKI-349 induced apoptosis activation in pNSCLC-1 cells, as the TUNEL-positively stained nuclei percentage was significantly increased after SKI-349 (5 μM, 72 h) treatment (Fig. 2E). Moreover the number of Annexin-V positively-stained pNSCLC-1 cell was increased after SKI-349 stimulation (Fig. 2F), again supporting apoptosis activation. The dual inhibitor induced significant pNSCLC-1 cell death, as the Trypan blue-positive cell percentage was dramatically increased (Fig. 2G).

Next, a pan-caspase inhibitor z-VAD-fmk [36–38] was utilized to block apoptosis activation. SKI-349 (5 μM, 72 h)-induced viability (CCK-8 OD) reduction (Fig. 2H) and cell death (tested by the increased number of Trypan blue-positive cells, Fig. 2H) were largely alleviated by z-VAD-fmk. These results implied that apoptosis activation should be the primary cause of SKI-349-induced cytotoxicity in pNSCLC-1 cells.

In other primary NSCLC cells (pNSCLC-2 and pNSCLC-3) and immortalized lines (A549 and NCI-H1944), the SphK1/2 dual blocker dose-dependently induced cell death in the primary and immortalized NSCLC cells, evidenced by the results from the Trypan blue-staining assays (Fig. 2I). Moreover, SKI-349 (5 μM) increased caspase-3 activity (Fig. 2J) and induced mitochondrial depolarization (JC-1 green monomer intensity increasing, Fig. 2K). The dual inhibitor induced apoptosis activation (tested by the TUNEL-positive nuclei ratio increase, Fig. 2L). In BEAS-2B cells and pEpi cells [21], SKI-349 (5 μM) treatment failed to induce significant cell apoptosis and death (Fig. 2M, N).

SKI-349 inactivates SphK in NSCLC cells

SKI-349 is a novel SphK1/2 dual inhibitor [20], we next analyzed its potential effect on SphK activity and SphK1/2 expression in NSCLC cells. Figure 3A demonstrated that SKI-349 (“SKI”, 5 μM) resulted in robust SphK activity reduction in patient-derived pNSCLC-1 and pNSCLC-2 cells. Consequently, pro-apoptotic total ceramide levels [39–41] were significantly increased (Fig. 3B). Notably, SphK1 and SphK2 protein and mRNA expressions were not significantly altered by the SKI-349 treatment in pNSCLC-1 and pNSCLC-2 primary cells (Fig. 3C, D). Increased ceramide could induce lysosomal release of cathepsin B and cathepsin D to cytosol, thereby induce Bid cleavage and Bax activation (Fig. 3E) [30, 42, 43]. We found that SKI-349 possibly activated cathepsin B and cathepsin D, as levels of cytosol cathepsin B and cathepsin D were both significantly increased in SKI-349-treated primary NSCLC cells. Moreover, tBid levels were increased as well (Fig. 3E).

Fig. 3. SKI-349 inactivates SphK in NSCLC cells.

Fig. 3

Open in a new tab

The patient-derived primary NSCLC cells (pNSCLC-1 and pNSCLC-2) were treated with SKI-349 (“SKI”, 5 μM) or the vehicle control (“Veh”, 0.1% DMSO), cells were further cultivated for 12 h; The relative SphK activity (A), cellular ceramide contents (B), and expression of listed proteins were tested (C–E). pNSCLC-1 primary cells were pretreated for 45 min with sphingosine-1-phosphate (S1P, 15 μM), K6PC-5 (15 μM) or 0.1% DMSO, followed by SKI-349 (“SKI”, 5 μM) stimulation and cells were further cultivated for 72 h; Cell viability (by measuring CCK-8 OD) and death (by measuring Trypan blue positively-stained cell ratio) were tested (F). pNSCLC-1 primary cells were treated with SKI-349 (1 or 5 μM), together with or without the short-chain C6 ceramide (10 μg/mL), and cells were further cultivated for 72 h, and cell viability (G) and cell death (H) were tested. pNSCLC-1 and pNSCLC-2 cells were treated with SKI-349 (“SKI”, 5 μM), PF-543 (25 μM), PF-543 (25 μM) plus ABC294640 (25 μM, “PF543 + ABC”), BML-258 (10 μM) or FTY720 (10 μM), or the vehicle control (“Veh”, 0.1% DMSO) for 72 h; Cell viability and death were tested (I–K). Expression of listed proteins in stable pNSCLC-1 cells expressing the scramble control shRNA (“shC”) or SphK1/2 shRNA lentiviral particles (“shSphK1 + shSphK2”) was shown (L); The “shSphK1 + shSphK2” pNSCLC-1 cells were further treated with or without SKI-349 (“SKI”, 5 μM) for 72 h, and cell viability (CCK-8 OD) and death (Trypan blue ratio) were tested (M). Data were presented as mean ± SD (n = 5). *P < 0.05 versus “Veh” treatment or shC treatment. #P < 0.05 versus DMSO pretreatment (F). #P < 0.05 (G, H and M). #P < 0.05 versus SKI-349 treatment (I–K). “n.s.” stands for non-statistical difference (P > 0.05). Experiments in this figure were repeated five times, and similar results were obtained.

To explore the link between SKI-349-induced SphK inactivation and NSCLC cell death, we exogenously added S1P [7, 8, 44, 45] and the SphK activator K6PC-5 [23, 46–48]. In pNSCLC-1 cells, SKI-349 (“SKI”, 5 μM, 72 h)-induced viability reduction and cell death (Fig. 3F) were ameliorated by S1P and K6PC-5. On the contrast, a short-chain C6 ceramide [25, 49–51] potentiated SKI-349 (1 and 5 μM, 72 h)-induced cytotoxicity in pNSCLC-1 cells (Fig. 3G, H). These results supported that SphK inactivation is important for SKI-349-induced NSCLC cell death.

We also compared the the activity of SKI-349 with other known SphK inhibitors, including the SphK1 inhibitor PF-543 [26, 27] and the SphK2 specific inhibitor ABC294640 [17, 24, 28, 29]. In pNSCLC-1 and pNSCLC-2 primary cells, SKI-349-induced viability reduction (Fig. 3I) and cell death (Fig. 3J) were more potent than PF-543 single treatment or plus ABC294640 co-administration (“PF543 + ABC”). In addition, SKI-349-induced cytotoxicity against primary NSCLC cells was more potent than other known SphK1 inhibitors, including BML-258 [52] and FTY720 (Fig. 3K) [53, 54]. These results suggested that inhibition of SphK1 or SphK2 each could result in NSCLC cell death. Yet SphK1 and SphK2 dual inhibition by SKI-349 shall result in even more stronger anti-NSCLC cell effect.

To silence SphK1 and SphK2, the SphK1 shRNA lentiviral particles and the SphK2 shRNA lentiviral particles were added together to pNSCLC-1 cells, and stable cells were established after puromycin selection. As shown, SphK1 and SphK2 were silenced in the stable cells (“shSphK1 + shSphK2”) (Fig. 3L). Co-silencing SphK1 and SphK2 inhibited cell viability and induced cell death (Fig. 3M) in pNSCLC-1 cells. Significantly, adding SKI-349 could further induce cytotoxicity in SphK1/2-silenced cells (Fig. 3M). These results supported that SphK1/2-indepednent mechanisms might also participate in SKI-349-induced killing of NSCLC cells.

SKI-349 induces Akt-mTOR inhibition, JNK activation, ROS production and oxidative injury in primary human NSCLC cells

Following SphK inactivation, S1P depletion and ceramide accumulation could result in Akt-mTOR (mammalian target of rapamycin) inactivation through multiple mechanisms [55–57]. Figure 4A showed that phosphorylations of Akt (at the Ser-473 residue) and S6K1 (at the Thr-389 residue) were largely inhibited after SKI-349 treatment (5 μM, 12 h) in pNSCLC-1 cells. Contrarily, ectopic expression of a constitutively-active S473D mutant Akt1 (caAkt1) [21] restored Akt and S6K1 phosphorylations in SKI-349-treated pNSCLC-1 cells (Fig. 4A). caAkt1 attenuated SKI-349-induced pNSCLC-1 cell death (Fig. 4B) and apoptosis (by measuring the TUNEL-positively stained nuclei percentage, Fig. 4C). These results implied that Akt-mTOR inhibition was important for SKI-349-induced NSCLC cell death.

Fig. 4. SKI-349 induces Akt-mTOR inactivation, JNK activation, ROS production and oxidative injury in primary NSCLC cells.

Fig. 4

Open in a new tab

The patient-derived pNSCLC-1 primary cells, with or without the constitutively-active S473D mutant Akt1 (caAkt1), were treated with SKI-349 (“SKI”, 5 μM), control cells were treated with the vehicle control (“Veh”, 0.1% DMSO) and cells were cultivated for designated time, expression of listed proteins was shown (A); Cell death (by measuring Trypan blue positively-stained cell percentage, (B)) and apoptosis (by measuring TUNEL-positively stained nuclei percentage, C) were tested. pNSCLC-1 and pNSCLC-2 cells were treated with SKI-349 (“SKI”, 5 μM) or the vehicle control (“Veh”, 0.1% DMSO), and cells were further cultivated for designated time; Expression of listed proteins (D), ROS contents (by measuring CellROX intensity (E)) and lipid peroxidation (by measuring TBAR activity, (F)) were tested. pNSCLC-1 and pNSCLC-2 cells were pretreated for 45 min with the antioxidant NAC (n-acetyl-L-cysteine 500 μM), the JNK inhibitor SP600125 (JNKi, 10 μM) or 0.1% DMSO, followed by SKI-349 (“SKI”, 5 μM) stimulation and cells were further cultivated for 72 h; Cell death (G) and apoptosis (H) were tested. Data were presented as mean ± SD (n = 5). *P < 0.05 versus “Veh” treatment. #P < 0.05 (A–C). #P < 0.05 versus “DMSO” group (G, H). Experiments in this figure were repeated five times, and similar results were obtained. Scale bar = 100 μm (E).

Another important mechanism responsible for ceramide-induced apoptosis is through initiating JNK activation [58–60]. In Fig. 4D SKI-349 provoked JNK activation by inducing JNK1/2 phosphorylation in pNSCLC-1 cells. Moreover, the dual inhibitor induced oxidative injury and increased CellROX intensity in pNSCLC-1 and pNSCLC-2 cells (Fig. 4E). In addition, increased TBAR activity, indicating lipid peroxidation, was detected in primary NSCLC cells after SKI-349 treatment (Fig. 4F). Significantly, the JNK inhibitor SP600125 or the antioxidant NAC both alleviated SKI-349-induced pNSCLC-1 cell death (Fig. 4G) and apoptosis (Fig. 4H) in NSCLC cells. Therefore, SKI-349 induced JNK activation, ROS production and oxidative injury in NSCLC cells.

SKI-349 silences BRD4 cascade in primary NSCLC cells

The bromodomain and extraterminal domain (BET) family protein BRD4 [61] directly binds to the acetylated-histones, regulating epigenetic processes [62–64]. BRD4 is essential for expression of key oncogenic genes, including Myc, cyclin D1 and Klf4 [63, 65]. Here in patient-derived pNSCLC-1 and pNSCLC-2 cells, SKI-349 (5 μM, 12 h) treatment induced downregulation of BRD4 mRNA and protein (Fig. 5A, B). As a result, mRNA expression of Myc, cyclin D1 and Klf4 was reduced (Fig. 5C). Next, a lentiviral BRD4-expressing construct (“oe-BRD4”) was transduced to pNSCLC-1 primary cells. It completely restored BRD4 protein expression in SKI-349-treated pNSCLC-1 cells (Fig. 5D). oe-BRD4 attenuated SKI-349-induced proliferation inhibition (EdU staining assays, Fig. 5E), cell apoptosis (by measuring TUNEL-positively nuclei ratio, Fig. 5F) and death (Fig. 5G) in pNSCLC-1 primary cells. Importantly, PF-543 single treatment or combination with ABC294640 failed to significantly affect BRD4 expression in pNSCLC-1 cells (Fig. 5H). These results implied that BRD4 downregulation could be the unique action by SKI-349, independent of SphK1/2 inhibition.

Fig. 5. SKI-349 silences BRD4 cascade in primary NSCLC cells.

Fig. 5

Open in a new tab

The patient-derived pNSCLC-1 and pNSCLC-2 cells were treated with SKI-349 (5 μM) or the vehicle control (“Veh”, 0.1% DMSO), cells were further cultivated for designated time; Expression of listed genes and proteins were shown (A–C). pNSCLC-1 cells, with or without the lentiviral BRD4-expressing construct (“oe-BRD4”), were treated with SKI-349 (5 μM), control cells were treated with the vehicle control (“Veh”, 0.1% DMSO) and cells were cultivated for designated time, expression of listed proteins was shown (D); Cell proliferation (by measuring EdU-positively stained nuclei percentage, (E)), death (by measuring Trypan blue-positive cell percentage, (F)) and apoptosis (by measuring TUNEL-positively stained nuclei percentage, (G)) were tested. pNSCLC-1 cells were treated with PF-543 (25 μM), PF-543 (25 μM) plus ABC294640 (25 μM, “PF543 + ABC”), or the vehicle control (“Veh”, 0.1% DMSO) for 12 h, expression of listed proteins was shown (H). Data were presented as mean ± SD (n = 5). *P < 0.05 versus “Veh” treatment. #P < 0.05 group (D–G). “n.s.” stands for non-statistical difference (P > 0.05). Experiments in this figure were repeated five times, and similar results were obtained.

SKI-349 administration inhibits NSCLC xenograft growth in nude mice

Tumor growth curve results demonstrated that SKI-349 administration potently inhibited the growth of pNSCLC-1 xenografts in nude mice (Fig. 6A). Compared to the xenografts with vehicle control treatment, the volumes of SKI-349-treated pNSCLC-1 xenografts were significantly lower (Fig. 6A). A described formula was utilized to calculate the estimated daily tumor growth (in mm3 per day [21, 22]). Daily tumor growth was impeded by the applied SKI-349 administration (Fig. 6B). At “Day-42” pNSCLC-1 xenografts of the two groups were isolated and individually weighted. SKI-349-treated pNSCLC-1 tumors were significantly lighter than vehicle-treated tumors (Fig. 6C). The mice body weights, as shown in Fig. 6D, were however not significantly different between the two groups.

Fig. 6. SKI-349 administration inhibits NSCLC xenograft in nude mice.

Fig. 6

Open in a new tab

The mice bearing pNSCLC-1 xenografts were subject to the applied SKI-349 administration or vehicle control treatment (“Veh”), with 10 mice per group (n = 10). The tumor volumes (A) and the mice body weights (D) were measured every 6 days (“Day-0” to “Day-42”); The estimated daily tumor growth (B) and weights of pNSCLC-1 xenografts at “Day-42” (C) were measured. At “Day-6” and “Day-12”, one pNSCLC-1 tumor per group were isolated, and the relative SphK activity was tested (E). Expression of listed genes and proteins in the described tumor tissues were tested (F, G, H, J, K, L and M). The relative lipid peroxidation intensity (TBAR activity, (I)) was examined as well. The proposed signaling pathway of the study (N). Data were presented as mean ± SD. *P < 0.05 versus “Veh” treatment. “n.s.” stands for non-statistical difference (P > 0.05).

To analyze the potential signaling changes in vivo, at “Day-6” and “Day-12” we isolated one pNSCLC-1 xenograft per group 6 h after SKI-349/vehicle administration. A total of four xenografts were obtained and tumor tissues were freshly analyzed. As shown, the SphK activity was significantly decreased in SKI-349-treated pNSCLC-1 tumor tissues (Fig. 6E). SphK1 and SphK2 protein expression was however not significantly changed (Fig. 6F). Akt-mTOR inactivation was detected in pNSCLC-1 xenograft tissues with SKI-349 administration, as Akt and S6K1 phosphorylations were significantly decreased (Fig. 6G). Furthermore, increased JNK1/2 phosphorylation (Fig. 6H) and lipid peroxidation (TBAR activity, Fig. 6I) were detected in pNSCLC-1 xenograft tissues with SKI-349 administration. On the other hand, BRD4 mRNA and protein levels were decreased in SKI-349-treated tumor tissues (Fig. 6J, K). Expression of BRD4-dependent mRNAs, Myc, cyclin D1 and Klf4, was decreased as well (Fig. 6L). Contrarily, levels of cleaved-caspase-3 and cleaved-PARP were significantly increased in SKI-349-treated pNSCLC-1 xenograft tissues, implying apoptosis induction (Fig. 6M).Therefore, in line with the signaling findings in vitro, SKI-349 administration induced Akt-mTOR inactivation, JNK activation, oxidative injury and BRD4 downregulation in pNSCLC-1 xenograft tissues.

Discussion

The results of the present study supported that targeting SphK1/2 by SKI-349 could result in profound anti-NSCLC cell activity. In primary human NSCLC cells and immortalized lines, SKI-349 potently inhibited cell proliferation, cell cycle progression, migration and viability, while provoking apoptosis. It was however non-cytotoxic to lung epithelial cells. The dual inhibitor inactivated SphK and resulted in ceramide accumulation in NSCLC cells (Fig. 6N). Significantly, there was a time-dependent response following treatment of SKI-349 treatment in NSCLC cells. SKI-349 first resulted in SphK1/2 inhibition, ceramide accumulation and signaling changes (12 h), cell cycle arrest (24 h), migration inhibition (24 h), and subsequent proliferation inhibition (48 h) and caspase/PARP activation (48 h), followed by apoptosis activation (72 h), viability reduction and cell death (72 h). In vivo, single dose SKI-349 administration robustly inhibited NSCLC xenograft growth in nude mice. Notably, SKI-349-caused anti-NSCLC cell activity was significantly more robust than the SphK1 inhibitor or plus the SphK2 specific inhibitor. Therefore, concurrent inhibition of SphK1 and SphK2 by SKI-349 resulted in robust killing of NSCLC cells.

Targeting SphK1/2, using genetic methods or pharmacologic agents, has been verified as an important strategy to inhibit NSCLC [11, 15, 16, 66, 67]. While the role of SphK1 in NSCLC has been well-studied [11–14, 66, 67], recent studies have focused on SphK2 in tumorigenesis and progression of NSCLC. Wang et al., have shown that SphK2 is overexpression in NSCLC, which is correlated with disease grade, lymph node status and NSCLC stage as well as tumor size and histology type [15]. Overexpressed SphK2 could be a valuable biomarker for prognosis and promising therapeutic target for NSCLC [15]. Yang et al., reported that ABC294640, the SphK2 inhibitor, sensitized TRAIL-induced NSCLC cell apoptosis possibly through upregulating death receptor4/5 (DR4/5) [17]. Liu et al., demonstrated that small interference RNA (siRNA)-induced silencing of SphK2 inhibited NSCLC cell proliferation and chemo-sensitized NSCLC cells to gefitinib-induced apoptosis [16].

A number of different SphK inhibitors were shown to interfere other signaling cascades in cancerous cells. SphK inhibition will induce ceramide accumulation, which can de-phosphorylate Akt by activating protein phosphatases (PP) PP1 and PP2A [56]. Moreover, SphK inhibition and ceramide accumulation could also initiate JNK activation [58–60] and ROS production [49, 51]. Sun et al., have shown that SKI-V, a SphK1 inhibitor, also inhibited Akt-mTOR activation in osteosarcoma cells [68]. Xun et al., demonstrated that the SphK2 inhibitor ABC294640 inhibited AKT-S6K1 but activated JNK signaling in colorectal cancer cells [24]. Yang et al., discovered that GDC-0349 induced Akt-mTORC1/2 blockage, SphK1 inactivation, ceramide accumulation, JNK activation and oxidative injury in NSCLC cells [69]. Yang and colleagues found that SphK2 inhibition or silencing potentiated TRAIL-induced apoptosis in NSCLC cells [17].

Due to various genetic mutations, Akt-mTOR overactivation is often detected in NSCLC, which is associated with tumorigenesis and cancer progression [70]. Indeed, Akt-mTOR overexpression and hyperactivation could be observed in over 90% of NSCLC adenocarcinoma [71–73]. Conversely, Akt-mTOR blockage would result in profound anti-NSCLC activity [70, 74, 75]. Our previous study has shown that PQR620, a novel and potent mTOR kinase blocker, efficiently inhibited NSCLC cell growth [21].

We here showed that Akt-mTOR inactivation, JNK activation and oxidative injury were detected in SKI-349-treated NSCLC cells and SKI-349-administrated pNSCLC-1 xenograft tissues. More importantly, caAkt1, the antioxidant NAC and the JNK inhibitor SP600125 all ameliorated SKI-349-induced NSCLC cell death. Therefore, alteration of these signaling cascades together could explain the superior anti-NSCLC activity by the novel SphK1/2 dual inhibitor (Fig. 6N).

BRD4 regulates epigenetic processes by associating with acetylated-histones [62–64]. BRD4 is also essential for the transcription elongation and expression of various oncogenes by associating with pTEFb (positive transcription elongation factor b) and by phosphorylating RNA polymerase II [63, 65]. Recent studies have proposed BRD4 as an important therapeutic target of NSCLC, and it is essential for the expression of Bcl-2, c-Myc, cyclin D1 and other oncogenic genes [63, 65]. Liao et al., have reported that BRD4 is overexpressed in NSCLC tissues and is correlated with histological type, lymph node metastasis, tumor stage and differentiation, and the poor prognosis [76]. Gao et al., showed that genetic silencing or pharmacological inhibition of BRD4 inhibited NSCLC cell growth possibly by downregulating eIF4E-mediated transcription [77]. BRD4 inhibition or depletion enhanced TRAIL-induced NSCLC cell apoptosis by inactivating NFκB cascade [78].

BRD4 physically associated with YAP/TAZ transcription factors, increasing expression of a number of different growth-regulating genes that are essential for the progression of cancer cells [79]. Frequent ARID1A (the AT-rich interactive domain 1A [SWI-like] gene) depletion, detected in 20% of all lung cancers, induced chromatin remodeling and glycolysis, inhibiting cell death induced by the BRD4 inhibitor JQ1 [80]. He et al., have shown that BRD4 inhibition and ARID2 depletion synergistically inhibited expression of DNA repair-related genes and induced robust cytotoxicity in cancer cells [81]. One important finding of the present study is that SKI-349 downregulated BRD4 and inhibited BRD4-dependent genes (Myc, cyclin D1 and Klf4) in primary NSCLC cells (Fig. 6N). More importantly, SKI-349-induced NSCLC cell death was ameliorated by ectopic overexpression of BRD4. BRD4 silencing by the SphK1/2 dual inhibitor could be another reason to explain its superior anti-NSCLC cell activity.

Novel and more efficient targeted therapies are urgently needed for NSCLC. We showed that targeting SphK1/2 by SKI-349 potently inhibited NSCLC cell growth in vitro and in vivo. However, the conclusion was based on the in vitro cellular studies and animal xenograft results. The efficacy and safety of the dual inhibitor against human NSCLC warrant further characterizations under clinical studies. The underlying mechanisms of SKI-349-induced anti-NSCLC cell activity need more exploration as well.

Supplementary information

Email copy regarding the author change (262.4KB, pdf)
Original author exchange form (2MB, pdf)
checklist form (1.7MB, pdf)
Author contribution form (300.6KB, pdf)
Figure S1 (1.1MB, pdf)

Acknowledgements

This work is supported by the National Natural Science Foundation of China (61927801) and by the pre-research project of doctors and returners of the Second Affiliated Hospital of Soochow University (SDFEYBS1902).

Author contributions

YX, KJ, LO, JL and WX proposed the whole project and designed the research. YX, KJ, LO, MS, YY, JL and WX performed the experiments, analyzed the data, carried out the statistics and organized all the figures. YX, KJ, LO, JL and WX collected the clinical samples and obtained the primary human cancerous and epithelial cells. All the listed authors participated in drafting the article and revising it, and are with final approval of the version submitted to the journal.

Data availability

All data are available upon request.

Competing interests

The authors declare no competing interests.

Ethics

All the protocols of the study were approved by Ethics Committee of Soochow University.

Footnotes

Edited by Professor Massimiliano Agostini

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally Yuhang Xue, Kanqiu Jiang, Li Ou, Mingjing Shen.

Contributor Information

Jingjing Lu, Email: marvel_j@163.com.

Weihua Xu, Email: xuweihua2208@suda.edu.cn.

Supplementary information

The online version contains supplementary material available at 10.1038/s41419-022-05049-4.

References

  • 1.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33. doi: 10.3322/caac.21654. [DOI] [PubMed] [Google Scholar]
  • 2.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi: 10.3322/caac.21590. [DOI] [PubMed] [Google Scholar]
  • 3.Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535–54. doi: 10.1016/S0140-6736(21)00312-3. [DOI] [PubMed] [Google Scholar]
  • 4.Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, et al. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet. 2016;388:1002–11. doi: 10.1016/S0140-6736(16)31340-X. [DOI] [PubMed] [Google Scholar]
  • 5.Zhang Y, Wang Y, Wan Z, Liu S, Cao Y, Zeng Z. Sphingosine kinase 1 and cancer: a systematic review and meta-analysis. PLoS One. 2014;9:e90362. doi: 10.1371/journal.pone.0090362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22:50–60. doi: 10.1016/j.tcb.2011.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets. 2008;9:662–73. doi: 10.2174/138945008785132402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Gangoiti P, Granado MH, Alonso A, Goni FM, Gomez-Munoz A. Implication of ceramide, ceramide 1-phosphate and sphingosine 1-phosphate in tumorigenesis. Transl Oncogenomics. 2008;3:81–98. [PMC free article] [PubMed] [Google Scholar]
  • 9.Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23:107–20. doi: 10.1016/j.ccr.2012.11.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, et al. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. Carcinogenesis. 2018;39:719–27. doi: 10.1093/carcin/bgy044. [DOI] [PubMed] [Google Scholar]
  • 11.Song L, Xiong H, Li J, Liao W, Wang L, Wu J, et al. Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-kappaB pathway in human non-small cell lung cancer. Clin Cancer Res. 2011;17:1839–49. doi: 10.1158/1078-0432.CCR-10-0720. [DOI] [PubMed] [Google Scholar]
  • 12.Zhu L, Wang Z, Lin Y, Chen Z, Liu H, Chen Y, et al. Sphingosine kinase 1 enhances the invasion and migration of non-small cell lung cancer cells via the AKT pathway. Oncol Rep. 2015;33:1257–63. doi: 10.3892/or.2014.3683. [DOI] [PubMed] [Google Scholar]
  • 13.Ma Y, Xing X, Kong R, Cheng C, Li S, Yang X, et al. SphK1 promotes development of nonsmall cell lung cancer through activation of STAT3. Int J Mol Med. 2021;47:374–86. doi: 10.3892/ijmm.2020.4796. [DOI] [PubMed] [Google Scholar]
  • 14.Wu X, Wu Q, Zhou X, Huang J. SphK1 functions downstream of IGF-1 to modulate IGF-1-induced EMT, migration and paclitaxel resistance of A549 cells: A preliminary in vitro study. J Cancer. 2019;10:4264–9. doi: 10.7150/jca.32646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wang Q, Li J, Li G, Li Y, Xu C, Li M, et al. Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer. Tumour Biol. 2014;35:363–8. doi: 10.1007/s13277-013-1051-1. [DOI] [PubMed] [Google Scholar]
  • 16.Liu W, Ning J, Li C, Hu J, Meng Q, Lu H, et al. Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer. Tumour Biol. 2016;37:6331–6. doi: 10.1007/s13277-015-4480-1. [DOI] [PubMed] [Google Scholar]
  • 17.Yang J, Yang C, Zhang S, Mei Z, Shi M, Sun S, et al. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer. Cancer Biol Ther. 2015;16:1194–204. doi: 10.1080/15384047.2015.1056944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, et al. SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models. Cancer Transl Med. 2017;3:109–21. doi: 10.4103/ctm.ctm_7_17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Dick TE, Hengst JA, Fox TE, Colledge AL, Kale VP, Sung SS, et al. The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines. J Pharm Exp Ther. 2015;352:494–508. doi: 10.1124/jpet.114.219659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hengst JA, Hegde S, Paulson RF, Yun JK. Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization. Bioorg Med Chem Lett. 2020;30:127453. doi: 10.1016/j.bmcl.2020.127453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Zha JH, Xia YC, Ye CL, Hu Z, Zhang Q, Xiao H, et al. The anti-non-small cell lung cancer cell activity by a mTOR kinase inhibitor PQR620. Front Oncol. 2021;11:669518. doi: 10.3389/fonc.2021.669518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Jiao PF, Tang PJ, Chu D, Li YM, Xu WH, Ren GF. Long non-coding RNA THOR depletion inhibits human non-small cell lung cancer cell growth. Front Oncol. 2021;11:756148. doi: 10.3389/fonc.2021.756148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Liu H, Zhang Z, Xu M, Xu R, Wang Z, Di G. K6PC-5 activates SphK1-Nrf2 signaling to protect neuronal cells from oxygen glucose deprivation/re-oxygenation. Cell Physiol Biochem. 2018;51:1908–20. doi: 10.1159/000495716. [DOI] [PubMed] [Google Scholar]
  • 24.Xun C, Chen MB, Qi L, Tie-Ning Z, Peng X, Ning L, et al. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo. J Exp Clin Cancer Res. 2015;34:94. doi: 10.1186/s13046-015-0205-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Chen MB, Jiang Q, Liu YY, Zhang Y, He BS, Wei MX, et al. C6 ceramide dramatically increases vincristine sensitivity both in vivo and in vitro, involving AMP-activated protein kinase-p53 signaling. Carcinogenesis. 2015;36:1061–70. doi: 10.1093/carcin/bgv094. [DOI] [PubMed] [Google Scholar]
  • 26.Ju T, Gao D, Fang ZY. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543. Biochem Biophys Res Commun. 2016;470:728–34. doi: 10.1016/j.bbrc.2016.01.053. [DOI] [PubMed] [Google Scholar]
  • 27.Schnute ME, McReynolds MD, Kasten T, Yates M, Jerome G, Rains JW, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012;444:79–88. doi: 10.1042/BJ20111929. [DOI] [PubMed] [Google Scholar]
  • 28.Guan S, Liu YY, Yan T, Zhou J. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor. Biochem Biophys Res Commun. 2016;476:230–6. doi: 10.1016/j.bbrc.2016.05.102. [DOI] [PubMed] [Google Scholar]
  • 29.Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology. 2010;151:5124–35. doi: 10.1210/en.2010-0420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R, et al. A gene-alteration profile of human lung cancer cell lines. Hum Mutat. 2009;30:1199–206. doi: 10.1002/humu.21028. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Wang Y, Liu YY, Chen MB, Cheng KW, Qi LN, Zhang ZQ, et al. Neuronal-driven glioma growth requires Galphai1 and Galphai3. Theranostics. 2021;11:8535–49. doi: 10.7150/thno.61452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Gao YY, Ling ZY, Zhu YR, Shi C, Wang Y, Zhang XY, et al. The histone acetyltransferase HBO1 functions as a novel oncogenic gene in osteosarcoma. Theranostics. 2021;11:4599–615. doi: 10.7150/thno.55655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zheng J, Zhang Y, Cai S, Dong L, Hu X, Chen MB, et al. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression. Cancer Lett. 2020;476:129–39. doi: 10.1016/j.canlet.2020.02.018. [DOI] [PubMed] [Google Scholar]
  • 34.Pena-Blanco A, Garcia-Saez AJ. Bax, Bak and beyond - mitochondrial performance in apoptosis. FEBS J. 2018;285:416–31. doi: 10.1111/febs.14186. [DOI] [PubMed] [Google Scholar]
  • 35.Degli Esposti M, Dive C. Mitochondrial membrane permeabilisation by Bax/Bak. Biochem Biophys Res Commun. 2003;304:455–61. doi: 10.1016/S0006-291X(03)00617-X. [DOI] [PubMed] [Google Scholar]
  • 36.Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol Cancer Ther. 2006;5:296–308. doi: 10.1158/1535-7163.MCT-05-0448. [DOI] [PubMed] [Google Scholar]
  • 37.Kumi-Diaka J, Sanderson NA, Hall A. The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell. 2000;92:595–604. doi: 10.1016/S0248-4900(00)01109-6. [DOI] [PubMed] [Google Scholar]
  • 38.Choi WS, Yoon SY, Oh TH, Choi EJ, O’Malley KL, Oh YJ. Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J Neurosci Res. 1999;57:86–94. doi: 10.1002/(SICI)1097-4547(19990701)57:1&#x0003c;86::AID-JNR9&#x0003e;3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  • 39.Young MM, Kester M, Wang HG. Sphingolipids: regulators of crosstalk between apoptosis and autophagy. J Lipid Res. 2013;54:5–19. doi: 10.1194/jlr.R031278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Henry B, Moller C, Dimanche-Boitrel MT, Gulbins E, Becker KA. Targeting the ceramide system in cancer. Cancer Lett. 2013;332:286–94. doi: 10.1016/j.canlet.2011.07.010. [DOI] [PubMed] [Google Scholar]
  • 41.Mullen TD, Obeid LM. Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med Chem. 2012;12:340–63. doi: 10.2174/187152012800228661. [DOI] [PubMed] [Google Scholar]
  • 42.Liu F, Li X, Lu C, Bai A, Bielawski J, Bielawska A, et al. Ceramide activates lysosomal cathepsin B and cathepsin D to attenuate autophagy and induces ER stress to suppress myeloid-derived suppressor cells. Oncotarget. 2016;7:83907–25. doi: 10.18632/oncotarget.13438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Heinrich M, Wickel M, Schneider-Brachert W, Sandberg C, Gahr J, Schwandner R, et al. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 1999;18:5252–63. doi: 10.1093/emboj/18.19.5252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, et al. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol. 2010;6:1603–24. doi: 10.2217/fon.10.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta. 2002;1585:193–201. doi: 10.1016/S1388-1981(02)00341-4. [DOI] [PubMed] [Google Scholar]
  • 46.Shao JJ, Peng Y, Wang LM, Wang JK, Chen X. Activation of SphK1 by K6PC-5 inhibits oxygen-glucose deprivation/reoxygenation-induced myocardial cell death. DNA Cell Biol. 2015;34:669–76. doi: 10.1089/dna.2015.2959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ji F, Mao L, Liu Y, Cao X, Xie Y, Wang S, et al. K6PC-5, a novel sphingosine kinase 1 (SphK1) activator, alleviates dexamethasone-induced damages to osteoblasts through activating SphK1-Akt signaling. Biochem Biophys Res Commun. 2015;458:568–75. doi: 10.1016/j.bbrc.2015.02.007. [DOI] [PubMed] [Google Scholar]
  • 48.Hong JH, Youm JK, Kwon MJ, Park BD, Lee YM, Lee SI, et al. K6PC-5, a direct activator of sphingosine kinase 1, promotes epidermal differentiation through intracellular Ca2+ signaling. J Invest Dermatol. 2008;128:2166–78. doi: 10.1038/jid.2008.66. [DOI] [PubMed] [Google Scholar]
  • 49.Yang L, Zheng LY, Tian Y, Zhang ZQ, Dong WL, Wang XF, et al. C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study. Exp Cell Res. 2015;332:47–59. doi: 10.1016/j.yexcr.2014.12.017. [DOI] [PubMed] [Google Scholar]
  • 50.Yu T, Li J, Sun H. C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro. Cancer Chemother Pharm. 2010;66:999–1003. doi: 10.1007/s00280-010-1374-1. [DOI] [PubMed] [Google Scholar]
  • 51.Ji C, Yang B, Yang YL, He SH, Miao DS, He L, et al. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene. 2010;29:6557–68. doi: 10.1038/onc.2010.379. [DOI] [PubMed] [Google Scholar]
  • 52.Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008;112:1382–91. doi: 10.1182/blood-2008-02-138958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 2003;169:2372–7. doi: 10.1097/01.ju.0000064938.32318.91. [DOI] [PubMed] [Google Scholar]
  • 54.Baek DJ, MacRitchie N, Pyne NJ, Pyne S, Bittman R. Synthesis of selective inhibitors of sphingosine kinase 1. Chem Commun (Camb) 2013;49:2136–8. doi: 10.1039/c3cc00181d. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Yang YL, Ji C, Cheng L, He L, Lu CC, Wang R, et al. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci. 2012;103:1538–45. doi: 10.1111/j.1349-7006.2012.02335.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Lin CF, Chen CL, Lin YS. Ceramide in apoptotic signaling and anticancer therapy. Curr Med Chem. 2006;13:1609–16. doi: 10.2174/092986706777441986. [DOI] [PubMed] [Google Scholar]
  • 57.French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharm Exp Ther. 2006;318:596–603. doi: 10.1124/jpet.106.101345. [DOI] [PubMed] [Google Scholar]
  • 58.Basu S, Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene. 1998;17:3277–85. doi: 10.1038/sj.onc.1202570. [DOI] [PubMed] [Google Scholar]
  • 59.Brenner B, Koppenhoefer U, Weinstock C, Linderkamp O, Lang F, Gulbins E. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem. 1997;272:22173–81. doi: 10.1074/jbc.272.35.22173. [DOI] [PubMed] [Google Scholar]
  • 60.Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996;380:75–9. doi: 10.1038/380075a0. [DOI] [PubMed] [Google Scholar]
  • 61.Wu X, Liu D, Gao X, Xie F, Tao D, Xiao X, et al. Inhibition of BRD4 suppresses cell proliferation and induces apoptosis in renal cell carcinoma. Cell Physiol Biochem. 2017;41:1947–56. doi: 10.1159/000472407. [DOI] [PubMed] [Google Scholar]
  • 62.White ME, Fenger JM, Carson WE., 3rd Emerging roles of and therapeutic strategies targeting BRD4 in cancer. Cell Immunol. 2019;337:48–53. doi: 10.1016/j.cellimm.2019.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Devaiah BN, Singer DS. Two faces of brd4: mitotic bookmark and transcriptional lynchpin. Transcription. 2013;4:13–7. doi: 10.4161/trns.22542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem. 2007;282:13141–5. doi: 10.1074/jbc.R700001200. [DOI] [PubMed] [Google Scholar]
  • 65.Hajmirza A, Emadali A, Gauthier A, Casasnovas O, Gressin R, Callanan MB. BET Family Protein BRD4: An emerging actor in NFkappaB signaling in inflammation and cancer. Biomedicines. 2018;6:16. [DOI] [PMC free article] [PubMed]
  • 66.Wang Y, Shen Y, Sun X, Hong TL, Huang LS, Zhong M. Prognostic roles of the expression of sphingosine-1-phosphate metabolism enzymes in non-small cell lung cancer. Transl Lung Cancer Res. 2019;8:674–81. doi: 10.21037/tlcr.2019.10.04. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Gachechiladze M, Tichy T, Kolek V, Grygarkova I, Klein J, Mgebrishvili G, et al. Sphingosine kinase-1 predicts overall survival outcomes in non-small cell lung cancer patients treated with carboplatin and navelbine. Oncol Lett. 2019;18:1259–66. doi: 10.3892/ol.2019.10447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Sun X, Shan HJ, Yin G, Zhang XY, Huang YM, Li HJ. The anti-osteosarcoma cell activity by the sphingosine kinase 1 inhibitor SKI-V. Cell Death Disco. 2022;8:48. doi: 10.1038/s41420-022-00838-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Yang H, Zhao J, Zhao M, Zhao L, Zhou LN, Duan Y, et al. GDC-0349 inhibits non-small cell lung cancer cell growth. Cell Death Dis. 2020;11:951. doi: 10.1038/s41419-020-03146-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC) Thorac Cancer. 2020;11:511–8. doi: 10.1111/1759-7714.13328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I, et al. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. Hum Pathol. 2011;42:214–26. doi: 10.1016/j.humpath.2010.05.025. [DOI] [PubMed] [Google Scholar]
  • 72.Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, et al. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer. 2010;70:94–102. doi: 10.1016/j.lungcan.2010.01.001. [DOI] [PubMed] [Google Scholar]
  • 73.Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S, Ooi A. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer. 2009;115:107–18. doi: 10.1002/cncr.23996. [DOI] [PubMed] [Google Scholar]
  • 74.Heavey S, O’Byrne KJ, Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev. 2014;40:445–56. doi: 10.1016/j.ctrv.2013.08.006. [DOI] [PubMed] [Google Scholar]
  • 75.Gately K, Al-Alao B, Dhillon T, Mauri F, Cuffe S, Seckl M, et al. Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. Lung Cancer. 2012;75:217–22. doi: 10.1016/j.lungcan.2011.06.012. [DOI] [PubMed] [Google Scholar]
  • 76.Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu JJ, et al. High level of BRD4 promotes non-small cell lung cancer progression. Oncotarget. 2016;7:9491–500. doi: 10.18632/oncotarget.7068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Gao Z, Yuan T, Zhou X, Ni P, Sun G, Li P, et al. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression. Cancer Biol Ther. 2018;19:407–15. doi: 10.1080/15384047.2018.1423923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Shi L, Xiong Y, Hu X, Wang Z, Xie C. BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-kappaB in NSCLC. Int J Med Sci. 2021;18:3090–6. doi: 10.7150/ijms.60776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Zanconato F, Battilana G, Forcato M, Filippi L, Azzolin L, Manfrin A, et al. Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4. Nat Med. 2018;24:1599–610. doi: 10.1038/s41591-018-0158-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Liu X, Li Z, Wang Z, Liu F, Zhang L, Ke J, et al. Chromatin remodeling induced by ARID1A loss in lung cancer promotes glycolysis and confers JQ1 vulnerability. Cancer Res. 2022;82:791–804. doi: 10.1158/0008-5472.CAN-21-0763. [DOI] [PubMed] [Google Scholar]
  • 81.He DD, Shang XY, Wang N, Wang GX, He KY, Wang L, et al. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. Oncogene. 2022;41:1397–409. doi: 10.1038/s41388-022-02176-2. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Email copy regarding the author change (262.4KB, pdf)
Original author exchange form (2MB, pdf)
checklist form (1.7MB, pdf)
Author contribution form (300.6KB, pdf)
Figure S1 (1.1MB, pdf)

Data Availability Statement

All data are available upon request.

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES